r/cancer • u/Ready-Shallot-2029 • 9d ago
Patient Mom B-Cell ALL diagnosis
My mom was recently diagnosed with acute lymphoblastic leukemia (B-cell type). She’s 49 years old and, until now, has always been completely healthy. I’m terrified and can’t imagine life without her.
She just finished her first week of inpatient chemo on the Hyper-CVAD regimen. Because this cancer is still fairly rare, I haven’t been able to find that much firsthand experience online. I’ve been turning to ChatGPT for answers, and from what I’ve learned, her chances of long-term remission are around 50–60% if she achieves MRD negativity after induction chemo.
I’m really hoping to connect with anyone who has gone through this—either personally or with a loved one. If you’re willing, I’d love to hear your success stories, encouragement, or experiences with Hyper-CVAD or other treatment plans.
Right now, I’m just trying to hold onto hope and learn as much as I can about what to expect from her treatment journey.
-1
9d ago
[removed] — view removed comment
2
u/Ready-Shallot-2029 9d ago
She has already started treatment. What do you mean you can give me a solution?
2
u/Lucy_Bathory 9d ago
Its just a grifter trying to take advantage of you, ignore them. Selling snake oil and shit.
2
u/TastyAdhesiveness258 9d ago
ALL occurs more frequent in pediatric acute leukemia but it is not all that rare among adult patients, just not as frequent as AML. Good thing is that many of the same robust treatment strategies developed for pediatric patients are just as applicable to adult treatment too. In addition to traditional chemotherapy, B-ALL can be effectively targeted with TKI drugs (for PH+ BCR::ABL mutation), immunotherapy such as Blinatumomab, and CAR-T treatment. ALL also has an excellent option for low-level MRD testing and monitoring using Clonoseq test. All of these tools provide good options for treating and monitoring ALL. I would suspect that 50–60% long-term remission is overly pessimistic, especially if patient achieves MRD-. Use AI and search tools to locate recent innovative research articles for better indication of current treatment options and outcomes rather than getting survival statistics based on older (less effective) treatment options. With a SCT, B-ALL patients that are MRD- before transplant have nearly 90% relapse free survival at +2 years, see graph in figure 1A of article;
https://pmc.ncbi.nlm.nih.gov/articles/PMC10345845/#appsec1